Argenx’s Stock Plummets After Deutsche Bank Downgrade: Investors Scrutinize Future Prospects
Argenx’s stock price has taken a significant hit following a valuation downgrade from Deutsche Bank, leaving investors wondering what’s next for the biotech company.
2 minutes to read